People in the News

Sep 11, 2018

Chitra Nayak

Invitae's board of directors this week expanded the number of members on its board to six members and appointed Chitra Nayak as a member. Nayak most recently served as chief operating officer of the real estate technology company Comfy, which was acquired by Siemens in June. Prior to that, Nayak worked at Funding Circle, an online peer-to-peer lending marketplace, and the cloud computing company Salesforce.com. Nayak will stand for re-election on Invitae's board in 2021.
Sep 11, 2018

Katherine Atkinson

Epic Sciences has appointed Katherine Atkinson as its chief commercial officer, charging her with the development of the firm's global commercial strategy. Atkinson joins Epic with two decades of life science and healthcare experience. Most recently, she served as vice president of business development at Edico Genome, where she established a global channel network and managed strategic partnerships. Prior to Edico she worked for Illumina, overseeing numerous teams, including molecular biology/PCR sales, inside sales, Latin America, and most recently global channel partners. She has also held positions at Fisher Scientific, Thermo Fisher, and Beckman Coulter.

Sep 10, 2018

Jack Challis

Cancer diagnostics shop Lucence Diagnostics appointed Jack Challis its healthcare analytics director. He will be based in San Francisco and will organize Lucence's streams of genomics data, as well as drive collaborations with research institutes and healthcare providers in the US. Challis cofounded CliniCast, which was acquired by Elekta in 2015. 

Sep 10, 2018

Edwin Hendrick

Biocept has appointed Edwin Hendrick as Senior Vice President and Chief Commercial Officer. Hendrick brings 25 years of sales and commercial leadership experience in the healthcare industry, with senior level commercial and operational positions at a variety of diagnostic and healthcare service companies. 

In his most recent position at GenomeDx, Hendrick developed the company's commercial strategy and launched its commercial offering. Prior to GenomeDx he served as executive vice president of sales and marketing at Plus Diagnostics. He also served as an executive with US Labs and led sales and marketing for Ventana Medical Systems after beginning his career in sales for Abbott Laboratories.

Sep 10, 2018

James Mullen

Thermo Fisher Scientific's board has elected James Mullen as a director, effective Nov. 8. He was appointed to the board's strategy and financing committee, and his term expires at the 2019 annual meeting. Mullen was CEO of Patheon until that firm's acquisition by Thermo Fisher in August 2017. Prior to Patheon, he was CEO and president of Biogen. 

Sep 07, 2018

Nikko Khazana and Mark Mozley

NantHealth has hired Nikko Khazana as senior VP for strategy and business development and Mark Mozley as SVP for global sales. Khazana had previously served as SVP of sales at CompanionDx Reference Lab. Mozley previously led sales efforts for life sciences and global strategic accounts at Clarivate Analytics. 

Sep 06, 2018

Steven Kafka

Steven Kafka has joined the board of directors of ArcherDX. He serves as a venture partner at Third Rock Ventures, and was previously the president and chief operating officer of Foundation Medicine, which is now owned by Roche. Before that, he was the COO and CFO of Aileron Therapeutics and VP of finance at Infinity Pharmaceuticals.

Sep 06, 2018

Linda Baddour, Gary Hendrickson

Waters announced today that has appointed Linda Baddour and Gary Hendrickson as directors of the firm.

Baddour has served as executive VP and CFO at PRA Health Sciences since 2007. Prior to PRA, she served as CFO at Pharmaceutical Product Development. Beforhand,  she also served as treasurer and chief accounting officer at the firm.

Prior to Waters, Hendrickson served as Chairman of  Valspar between 2012 and 2017, and CEO since 2011. Prior to CEO, Hendrickson acted as COO, president of several business units, and corporate VP and President of the firm's Asia Pacific branch.

Sep 04, 2018

Wang Shi

Wang Shi has been appointed as co-chair of BGI Group, where he will assist with business management and operations. He is the founder and former chairman of China Vanke, a residential real estate developer.

Sep 04, 2018

Katherine Atkinson

Epic Science has appointed Katherine Atkinson as chief commercial officer, tasked with the development of Epic's global commercial strategy.

Atkinson joins Epic with two decades of life science and healthcare experience, most recently as vice president of business development at Edico Genome. Prior to Edico, Atkinson worked for Illumina, where she oversaw a variety of sales teams. She has also held positions at Fisher Scientific, Thermo Fisher, and Beckman Coulter.

Aug 30, 2018

Angeline McCabe

Veracyte has named Angeline McCabe as its vice president of investor relations and corporate communications, effective immediately. McCabe had been vice president of investor relations at WellCare Health Plans, and before that, she held investor relations and corporate communications positions at Health Net and Valeant Pharmaceuticals. 

Aug 29, 2018

Elaine Lyon

Elaine Lyon has joined the HudsonAlpha Institute for Biotechnology as director of the HudsonAlpha Clinical Services Lab. Lyon comes to HudsonAlpha from the University of Utah, where she served as medical director for molecular genetics, genomics, and pharmacogenetics at ARUP Laboratories. She also held a faculty position at the University of Utah School of Medicine. She holds a PhD in medical genetics from the University of Alabama at Birmingham, and completed a fellowship in clinical molecular genetics at the University of Utah. She has served as president of the Association for Molecular Pathology and is a member of the American College of Medical Genetics and Genomics.

Aug 28, 2018

Marvin Caruthers

Marvin Caruthers has joined the board of directors of ArcherDx, a Boulder, Colo.-based molecular pathology firm. Caruthers is a distinguished professor of chemistry and biochemistry at the University of Colorado and cofounded several biotech companies including Amgen, Applied Biosystems, and Array BioPharma. He also was awarded the National Medal of Science for 2006.

Aug 28, 2018

Wendy Britten

Congenica has named Wendy Britton chief financial officer, effective Sept. 1. Britten joins the British clinical genomics interpretation software vendor from AstraZeneca, where she led group finance business performance. In addition to the normal CFO responsibilities, Britten will have a say in Congenica's business development and future fundraising, the company said. In announcing Britten's hiring, Congenica disclosed that it raised $13.5 million in a Series B that concluded in April 2017, higher than the $10 million reported two months earlier.

Aug 28, 2018

Roland Diggelmann, Michael Heuer

Roland Diggelmann will be stepping down as CEO of Roche Diagnostics, effective Sept. 30, to pursue his career elsewhere. Michael Heuer, Roche Diagnostics' region head for Europe, the Middle East, Africa, and Latin America, will step in as interim CEO of Roche's diagnostics division and will become a member of the corporate executive committee. He was previously with Boehringer Mannheim, which Roche acquired in 1998. Heuer holds a PhD in chemistry from the University of Kiel in Germany.

Aug 27, 2018

Benjamin Bielak

iSpecimen has announced that it has appointed Benjamin Bielak as chief information officer. Bielak will lead development of the firm's iSpecimen Marketplace, an online platform that connects biomedical rsearchers with specimens needed for developing new diagnostics, treatments, and cures. Prior to iSpecimen, Bielak served as chief information officer at GNS Healthcare. Before GNS, Bielak served as chief information officer at Dovetail Health. 

Aug 27, 2018

Soo Khee Chee

Clearbridge Health has appointed Soo Khee Chee to its medical advisory board. He is a professor of surgery at the National University of Singapore and helped establish the National Cancer Centre Singapore. He also served as senior vice deal of clinical, academic and faculty affairs at Duke-NUS Graduate Medical School Singapore.

Aug 23, 2018

Paul Holt

Paul Holt, chief financial officer of NantHealth, will resign from his position effective Sept. 11. According to a filing with the US Securities and Exchange Commission, it is an amicable split, done for unspecified personal reasons. Holt will assume an advisory role during a transition period through Dec. 31, the company said.

Aug 23, 2018

John Quackenbush

Veteran computational biologist John Quackenbush has promoted to chair of the Department of Biostatistics at the Harvard T.H. Chan School of Public Health. Quackenbush, long a researcher in computational biology and bioinformatics at Dana-Farber Cancer Center and Harvard Medical School, founded the HSPH master's program in computational biology and quantitative genetics. He has been on the Harvard faculty since 2005. Quackenbush replaced Xihong Lin, who is shifting her focus to the Genome Sequencing Program of the National Human Genome Research Institute and the Trans-Omics Precision Medicine Program of the National Heart, Lung, and Blood Institute, according to a Harvard announcement.

Aug 23, 2018

Marty Weems

Advanced Genomics Solutions has appointed Marty Weems as VP of strategic business. Weems previously served as VP of sales and strategic business with EXOS for 11 years. 

Aug 22, 2018

Michael Klimas

Indi Molecular has appointed Michael Klimas its senior vice president of strategy and technical business development. He most recently was Merck Research Laboratories' executive director translational biomarker immuno-oncology and cardiometabolic lead. He started his career at AstraZeneca in neuroscience drug discovery, and he was a founding member of GE Medical Systems' molecular imaging strategy and business development effort. 

Aug 17, 2018

Michelle Griffin

HTG Molecular Diagnostics has appointed Michelle Griffin to its board of directors. Griffin currently serves as a board member and chair of the audit committee for Acer Therapeutics. She has previously served as a board member and as audit committee chair for multiple firms since 2016, including PhaseRx, OncoGenex Pharmaceuticals, and Sonus Pharmaceuticals. In addition, Griffin has served in executive roles at OncoGenex, Trubion Pharmaceuticals, Dendreon, and Corixa over the past two decades.

Aug 16, 2018

Jeffrey Henderson

Becton Dickinson has elected Jeffrey Henderson to its board of directors. Henderson is the non-executive chairman of the board of Qualcomm, serves on the boards of FibroGen and Halozyme Therapeutics, and is an advisory director to Berkshire Partners. He previously served as CFO of Cardinal Health for nearly 10 years and has also held positions at Eli Lilly and General Motors.

Aug 14, 2018

Christopher Bernard, Chris Emery

Curetis announced that Christopher Bernard has resigned as CEO and president of Curetis USA, as well as from the firm's management board, effective Aug. 31. The company has appointed Chris Emery to replace him, effective Sept. 1.


Bernard joined Curetis USA as CEO and president in July 2016 and had served on Curetis NV's management board since June 2018.

Emery has more than 20 years of commercial experience in the diagnostic and pharmaceutical industries. Prior to Curetis, Emery served as chief commercial officer of North America for Menarini Silicon Biosystems, where he directed US sales and business development activities for the DepArray Nxt molecular device and integrated the CellSearch Circulating Tumor Cell test. He has also served as general manager for Abbott's PersonalizeDx cancer diagnostics laboratory division and has held senior level management roles at CombiMatrix, Response Genetics, and US Labs.

Aug 09, 2018

Albert Parker

OncoCyte has appointed Albert Parker as its chief operating officer. According to the company, Parker is an attorney and executive with more than 25 years of pharmaceutical, biotech, and healthcare experience. Prior to joining OncoCyte, Parker served as the managing shareholder of GC Legal Advisors, where he represented and advised public and privately held companies, primarily in the life sciences industry. Among other prior roles, Parker has also served as executive VP, general counsel, and corporate secretary at Sunovion Pharmaceuticals, senior VP and chief counsel for Wyeth Pharmaceuticals, and partner at Schnader Harrison Segal & Lewis.

Pages

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.